In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.
· On May 30, 2019, Jafron Biomedical Co. attended a conference at the Vicenzia convention where it organized the “2019 Jafron International Adsorption” satellite meeting. Several tests were conducted on the Jafron hemoperfusion cartridge which showed that it was safe and had good hemodynamics.
· In December, 2017, Spectral Medical announced that it received FDA approval for its Spectral Apheresis Machine (SAM) which was developed in order to support the company’s Toraymyxin or PMX therapy and prevent the risk of septic shock in patients.